Farmaprojects will be present in CPHI 2022, the biggest pharma industry event - Farmaprojects

news

24/11/2022

Farmaprojects will be present in CPHI 2022, the biggest pharma industry event

Farmaprojects will be present in the 2022 edition of CPHI, one of the most important international pharma industry events that this year will take place in Frankfurt (Germany) from November 1st to 3rd.

In this edition, more than 1.500 exhibitors of products, services and solutions within the pharma sector take part and meet new customers and potential partners, as well as strengthen business relationships. Simultaneously, the ICSE, P-MEC, FDF, InnoPack & BioProduction fairs are held.

Farmaprojects is going to be at Polpharma stand as every year . It will inform attendees of its project, based on delivering excellence to its B2B partners and focus on delivering first class out-licensing services and reliable supply to all their pharma clients in the world of generics. In addition, it will take part in the complementary activities of the event.

With its presence in one of the main international meeting points for the pharmaceutical industry, Farmaprojects reaffirms its global approach and its goal of becoming the preferred trusted partner of the industry.

© 2022, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department.
DISCLAIMER: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

© 2022, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department.
DISCLAIMER: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.